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. "We were starting to think we were going to obstruct their gut with all the cellulose from the capsules." So Plexxikon, together with its partner, Swiss drug maker Roche, developed a new formulation of the drug that was more easily absorbed by the body.
That reformulation proved crucial. On 26 August, researchers published the first findings from a small clinical trial of the reformulated drug. In one arm of the study 1 
, tumours shrank by at least
Telescopes in space could help pin down the risk of a deadly impact.
NASA panel weighs asteroid danger
Some time in the next decade, a US president will probably be presented with this dilemma: is it worth spending US$1 billion to deflect a space rock that may never hit Earth?
A NASA panel is wrestling with this question, which is growing more pertinent as scientists' ability to find asteroids that pose a potential risk, termed near-Earth objects (NEOs), outstrips their capacity to track them accurately. The Ad-Hoc Task Force on Planetary Defense, set up to suggest ways for the agency to protect Earth against a deadly impact, is expected to release its report next month. But public deliberations and interviews with its members have revealed their thinking.
The dilemma stems from a 2005 congressional mandate directing NASA to log 90% of the estimated 20,000 NEOs larger than 140 metres in diameter by 2020. NASA seems unlikely to meet the goal, but the agency is stepping up its detection and tracking of smaller objects.
That will create a new problem: if the pace of NEO detections (see graph) grows but precision tracking of orbits lags behind, observers will start to find more rocks -perhaps a few per yearthat seem, at first, to have a significant chance of hitting Earth, say panel members. "I don't think that issue has been understood outside the NEO community, " says Lindley Johnson, NEO programme officer at NASA and a member of the panel. Launching missions to track or deflect all potential asteroid threats will be prohibitively expensive, but even a small probability of regional or global devastation may not be politically palatable. One solution from the panel is to increase the amount that the United States invests in NEO detection and tracking from the current $5.5 million a year. The panel may also recommend the launch of a survey telescope into a solar orbit similar to that of Venus. It would orbit faster than Earth and, looking outwards, would see asteroids in Earth-crossing orbits more often than would ground-based instruments (see diagram). This could improve follow-up observations, narrow estimated trajectories and remove as many asteroids as possible from the threat list. It could also spot and track asteroids on the sunward side of Earth, removing a worrisome blind spot in ground-based surveys. "It is a wonderful rapid technique to track bodies down to 140 metres and smaller, " says Tom Jones, a former astronaut and panel co-chair.
Ball Aerospace and Technologies Corporation, a manufacturer of spacecraft based in Boulder, Colorado, has proposed building such a remote scope at a cost of $600 million. Missions to deflect all potential threats will be prohibitively expensive.
Rare victory in fight against melanoma
Melanoma tumours shrank after patients took PLX4032 for 2 weeks. The Plexxikon team also found that PLX4032 was remarkably specific for the mutated form of B-RAF, binding relatively poorly, if at all, to more than 200 other proteins, including unmutated B-RAF. That selectivity, says Hirth, probably explains why patients were able to take PLX4032 at such high doses without severe side effects.
Despite the promising results, PLX4032 has been tested in only a small number of patients and it is too early to declare the drug a success, cautions Chapman. The next stage is a larger trial in 700 patients, which began in January.
And although PLX4032 has clear short-term effects on tumour growth, researchers don't yet know whether the drug will allow patients to live significantly longer. Melanoma tumours quickly become resistant to PLX4032, and researchers estimate that tumour growth typically resurges about seven months after the start of therapy. "These cancer cells are smart," says Legos. "You shut down one specific pathway, and they will find a different way to survive." Nevertheless, Legos notes that, given the short survival of patients with advanced melanoma, it seems likely that drugs such as PLX4032 will have some effect on lifespan.
To overcome resistance, PLX4032 will be tested in combination with other drugs. In addition to the larger trial of PLX4032 alone, Plexxikon is planning a trial that will combine PLX4032 with an experimental drug that blocks MEK, another protein involved in the cell-growthpromoting pathway. Meanwhile, GSK is recruiting patients for a clinical trial combining two of its own experimental drugs, which respectively block mutated B-RAF and MEK. For now, the promising results from PLX4032 highlight the power of targeting specific genetic mutations in tumours, says Yardena Samuels, a cancer geneticist at the National Human Genome Research Institute in Bethesda, Maryland. "It's a very important development, not just for melanoma, but for the entire cancer field." ■ Heidi Ledford
